Burlingame Center for Psychiatric Research and Education

Mission:  To promote excellence in clinical care through research and education. Current Staff Clinical Information Management Professional Education Current Research Studies Selected Publications and Presentations

Current Staff:
 

Clinical Information Management:

• Burlingame Center staff operates the hospital's computerized clinical decision support system (CEMS - The Clinical Evaluation and Monitoring System).

• The Burlingame Center supports quality management and program evaluation activities, monitors clinical care (e.g., evidence-based practices), maintains practice guideline documents, and conducts research related to hospital operations.

Top

Professional Education Activities Include:

• Grand Rounds: Weekly educational conferences covering a variety of topics related to mental health and psychiatric practice.  Grand Rounds are accredited for continuing medical education and are presented Wednesday mornings 8:00 AM - 9:15 AM, September through June.

• Psychopharmacology and Neuroscience Rounds: This series focuses on applied psychopharmacology and research on brain structure and function.  Held once monthly from September through June on Thursday at 12:00 noon in the Hartford Room, Commons Building, The Institute of Living.

Top

Current Research Studies (selected list):

Top

Selected Publications and Presentations (last updated 6/19/08):

• Augustin SG, Puzantian T, Caley CF, Marken PA, Richards AL, Levin GM.  Psychiatric pharmacists (letter).  Am J Psychiatry, 158:2090, 2001.
• Blank K, Szarek BL, Goethe JW.  Metabolic abnormalities in patients with major depressive disorder.  Presented at the annual meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Blank K, Szarek BL, Goethe JW.  The influence of dementia on the treatment of depression in geriatric inpatients.  Presented at the annual meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Boerth JM, Caley CF, Goethe JW.  Interpreting serum risperidone concentrations.  Pharmacotherapy, 25(2):299–302, 2005.
• Boerth JM, Caley, CF.  Possible case of mania associated with ma-huang.  Pharmacotherapy, 23(3):383-3, 2003.
• Boerth JM, Strong KM.  The clinical utility of milk thistle (Silybum marianum) in cirrhosis of the liver.  J Herb Pharmcother, 2(2):11-7, 2002.
• Bohannon RW, Maljanian R, Goethe JW.  Screening for depression in clinical practice:  Reliability and validity of a five-item subset of the CES-Depression.  Perceptual and Motor Skills, 97:855-861, 2003.

• Bullock K, Szarek BL, Goethe JW.  Racial differences in prescribing practices in the treatment of schizophrenia.  To be presented at the annual meeting of the American Psychiatric Association, Washington, D.C., May 2008.

• Burrell M, Jaffe A.  Personal meaning, drug use, & addiction: An evolutionary constructivist perspective.  J Constructivist Psychology, 12(1):41-63, 1999.
• Caley CF.  Atypical antipsychotics in schizophrenia: evaluating adherence and relapse.  Presented at the 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, The Broadmoor Hotel, Colorado Springs, Colorado, April 15, 2007.

• Caley CF.  Treatment outcomes in schizophrenia: current issues and emerging options.  Symposium chair, 10th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs, Colorado, April 2007.

• Caley CF.  More than the baby blues:  identification and management of postpartum depression.  Presented at the 155th Annual Meeting and Exposition of the American Pharmacy Association, Georgia Convention Center, Atlanta, Georgia, March 18, 2007.

• Caley CF.  Medication management for bipolar disorder:  advantages and disadvantages.  Presented at the Depression and Bipolar Support Alliance, Hartford, CT, December 2006.

• Caley CF.  Treatment resistant depression.  Presented at the 10th Annual Northeastern Psychiatric Pharmacotherapy Symposium, Northampton, Massachusetts, September 2006.

• Caley CF.  From San Diego to Baltimore.  Outgoing presidential address presented to members of the College of Psychiatric and Neurologic Pharmacists at the 9th annual meeting, Baltimore Waterfront Marriott Hotel, Baltimore, Maryland, April 25, 2006.

• Caley CF.  Essential fatty acids and treatment response.  Presented at the annual meeting of NAMI– CT, Wallingford, Connecticut, October 2005.

• Caley CF.  Keeping our eyes on the ball: monitoring the atypical antipsychotics.  Presented at the West Virginia University School of Medicine’s 9th Annual Psychosis Conference, Morgantown, West Virginia, September 9, 2005.
• Caley CF, Cooper CK.  Ziprasidone:  the fifth atypical antipsychotic.  Ann Pharmacother, 36:839–51, 2002.
• Caley CF, Kando JC.  SSRIs–Finding the right dose.  Journal of Psychiatric Practice, 8:33–40, 2002.
• Caley CF, Silvia RJ.  Cytochrome P–450 drug interactions and the selective serotonin reuptake inhibiting antidepressants.  Connecticut Medicine, 64:721–4, 2000.
• Cardoni AA, Woolley SB.  Use of last observation carried forward (LOCF) in clinical efficacy trials: review of 352 antidepressant studies.  Clinical Trials, (accepted) 2008.

• Cardoni AA, Woolley SB, Goethe JW.  LOCF (Last Observation Carried Forward) and distortion of findings in a psychotropic drug clinical study.  Presented at the annual meeting of the American Psychiatric Association, San Diego, California, May 2007.

• Cardoni AA, Woolley SB, Piez DA, Goethe JW.  Bupropion augmentation versus usual care in the treatment of patients with treatment-resistant depression.  Presented at the 10th annual meeting of the College of Psychiatric and Neurologic Pharmacists, The Broadmoor Hotel, Colorado Springs, Colorado, April 17, 2007.
• Cardoni AA, Woolley SB, Piez DA, Goethe JW.  Bupropion augmentation versus usual care in the treatment of patients with treatment-resistant depression.  Poster presented at the annual meeting of the U.S. Psychiatric & Mental Health Congress, New Orleans, Louisiana, November 17, 2006.
• Cardoni AA.  Bipolar update.  Presented to the Department of Psychiatry, The Institute of Living, Hartford, Connecticut, September 2006.

• Cardoni AA, Woolley SB, Piez DA, Goethe JW.  Bupropion augmentation versus usual care in the treatment of patients with treatment-resistant depression.  Presented at the annual meeting of the American Psychiatric Association, Toronto, Canada, May 2006.

• Cardoni AA, Woolley SB, Piez DA, Goethe JW.  Treatment-resistant depression: changes in symptoms and functioning in a clinical sample.  Presented at the annual meeting of the American Psychiatric Association, Toronto, Canada, May 2006.

• Cardoni AA.  Antipsychotics in OCD. Provided comments on structure-activity relationships among antipsychotic agents used in treatment of OCD.  Presented at Psychopharmacology/Neuroscience Rounds, The Institute of Living, Hartford, Connecticut, November 2005.

• Cardoni AA.  Anticonvulsants in the treatment of anxiety disorders.  Presented at Psychopharmacology/Neuroscience Rounds, The Institute of Living, Hartford, Connecticut, October 2005.
• Cardoni AA, Woolley SB, Goethe JW.  LOCF use in clinical efficacy trials: review of 260 antidepressant studies.  Presented at the annual meeting of the American Psychiatric Association, Atlanta, Georgia, May 2005.
• Cardoni AA.  Depression, SSRIs and suicide.  Causal relationship or guilt by association?  Presented at Psychopharmacology/Neuroscience Rounds, The Institute of Living, Hartford, Connecticut, April 2004.

• Carter AL, Wilber C, Sahl R.  Motivational interviewing techniques and the harm-reduction model in a short-term substance-abuse group for adolescents with psychiatric problems.  Connecticut Medicine, 69: 535-541, 2005.

• Diefenbach GJ, Goethe JW.  Clinical interventions for late-life anxious depression.  Clinical Interventions in Aging, 1: 41-50, 2006.

• Dornelas EA, Botticello AL, Goethe JW, Fisher EH.  Validity of a brief measure of post-hospital adjustment for psychiatric patients.  Comprehensive Psychiatry, 42:410-415, 2001.
• Ehret MJ, Sopko MA, Levine A.  Iloperidone: a novel atypical antipsychotic for the treatment of schizophrenia.  Formulary, 43:190-203, 2008.
• Ehret MJ.  STAR-D: Where are we Now?  Presented at Northeastern Psychiatric Pharmacy Symposium, Norhampton, MA, October 2007.
• Ehret MJ, Levin GM, Narasimhan M, Rathinavelu A.  Venlafaxine induces p-glycoprotein in human Caco-2 cells.  Hum Psychopharmacol Clin Exp, 22:49-53, 2007.
• Ehret MJ.  Pharmacogenomics of antidepressant medications.  Journal of Pharmacy Practice, 19:342-52, 2006.
• Ehret MJ, Chavez B.  A review of the STAR*D trial.  Journal of Pharmacy Practice, 19:353-60, 2006.
• Ehret MJ, Levin GM.  The long-term use of atypical antipsychotics in bipolar disorder.  Pharmacotherapy, 26(8):1134-47, 2006.
• Feret BM, Caley CF.  Possible hypothyroidism associated with quetiapine.  Ann Pharmacother, 34:483–6, 2000.
• Fischer EH, Dornelas EA, Goethe JW.  Characteristics of people lost to attrition in psychiatric follow-up studies.  J Nervous & Mental Disease, 189:49-55, 2001.
• Fogg-Waberski JH, Szarek BL, Knauft RF.  Electroconvulsive therapy for treatment of refractory depression in a patient with cystic fibrosis.  Journal of ECT,  22:72-3, 2006.

• Goethe JW.  Stuck in the black box: a patient safety approach to prescribing antidepressants.  To be presented at the annual meeting of the American Psychiatric Association, Washington, D.C., May 2008.

• Goethe JW, Woolley SB, Cardoni AA, Woznicki B, Piez DA.  Long-term follow-up of patients with major depressive disorder:  changes in symptoms, treatment and side effects.  To be presented at the annual meeting of the American Psychiatric Association, Washington, D.C., May 2008.
• Goethe JW, Szarek BL, Caley CF.  Metabolic syndrome and depression: a review.  Depression: Mind and Body, 3(4):138-149, 2008.

• Goethe JW, Blank K, Szarek BL.  Metabolic risk factors in geriatric inpatients with major depressive disorder.  Presented at the annual meeting of the American Psychiatric Association, San Diego, California, May 2007.

• Goethe JW, Szarek BL, Woolley SB, Caley CF.  Metabolic abnormalities in psychiatric inpatients.  Presented at the annual meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Goethe JW, Szarek BL, Woolley SB, Caley CF.  Metabolic syndrome in psychiatric inpatients. Presented at the annual meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Goethe JW.  Expanding the do no harm mandate.  Invited article.   Connecticut Medicine, 71:499-500, 2007.
• Goethe JW, Szarek BL, Caley CF, Woolley SB.  Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review.  J Clin Psychiatry, 68:22-8, 2007.
• Goethe JW, Woolley SB, Cardoni AA, Woznicki B, Piez DA.  SSRI discontinuation:  side effects and other factors that influence medication adherence.  J Clin Psychopharmacol, 27(5):451-8, 2007.

• Goethe JW, Woolley SB, Piez DA, Woznicki B.  Hopelessness and suicidality three months post-hospital discharge.  Presented at the annual meeting of the American Psychiatric Association, Toronto, Canada, May 2006.

• Goethe JW, Melman D.  Mind and brain: together again.  Invited article.  Connecticut Medicine, 70:599-600, 2006.

• Goethe JW, Szarek BL, Caley CF.  Metabolic syndrome in psychiatric inpatients taking antipsychotics.  Presented at the annual meeting of the American Psychiatric Association, Atlanta, Georgia, May 2005.

• Goethe JW, Woolley SB.  Association between SSRI side effects and adherence to modern SSRIs.  Presented at the annual meeting of the American Psychiatric Association, Atlanta, Georgia, May 2005.

• Goethe JW.  Antibiotics and mental disorder.  Editorial.  Connecticut Medicine, 69:649, 2005.
• Goethe JW, Szarek BL, Caley CF, Piez DA.  QTc prolongation associated with ziprasidone.  Presented at the annual meeting of the American Psychiatric Association, New York, New York, May 2004.
• Goethe JW.  Evidence based medicine: what’s new – what’s not – what’s needed.  Invited paper.  Connecticut Medicine (Reflections on Medicine), 6:637-8, 2003.
• Goethe JW, Horowitz S, Maljanian R, Wolf S, Hernandez P, Cabrera Y.  The impact of depressive symptoms on the functional status of inner city patients with asthma.  Annals of Allergy, Asthma, & Immunology, 87(3):205-10, 2001.
• Goethe JW, Bronzino JD.  Design issues in developing clinical decision support and monitoring systems.  The Biomedical Engineering Handbook, Volume II, CRC Press, Boca Raton, Florida, pp 1801-1808, 2000.
• Goethe JW, Price AL.  Herbal medicines with psychiatric indications; a review for practitioners.  Connecticut Medicine, 64:347-351, 2000.
• Goethe JW, Woolley SB.  GAF and LOS as predictors of outcome in depression.  Presented at the annual meeting of the American Psychiatric Association, Washington, D.C., May 1999.
• Goethe JW, Dornelas EA, Gruman C.  Predicting service utilization after psychiatric hospitalization.  Comprehensive Psychiatry, 40:192-7, 1999.
• Gugger JJ, Caley CF.  Clozapine treatment in a patient with a persistently low neutrophil count.  Poster presented at the 10th annual meeting of the College of Psychiatric and Neurologic Pharmacists, The Broadmoor Hotel, Colorado Springs, Colorado, April 17, 2007.
• Gugger JJ, Caley CF, Goethe JW, Szarek BL, Ehret MJ, Woolley, SB.  The pharmacogenomics of antidepressant tolerance.  Poster presented at the 10th annual meeting of the College of Psychiatric and Neurologic Pharmacists, The Broadmoor Hotel, Colorado Springs, Colorado, April 17, 2007.
• Gugger JJ, Caley CF.  Clozapine treatment in a patient with a persistently low neutrophil count.  Clinical Schizophrenia and Related Psychoses, 1:270–2, 2007.
• Jaffe AJ, Wilber CH, Rounsaville BJ.  Psychosocial therapies for cocaine dependence:  A controlled study.  Presented at the annual meeting of the American Psychiatric Association, New York, New York, May 2004.
• Jaffe AJ, Wilber CH, Rounsaville BJ.  Substance expectations therapy for cocaine abuse:  A controlled study.  Presented at the annual meeting of the American Psychiatric Association, New York, New York, May 2004.
• Levin GM, Bowles TA, Ehret MJ, et al.  Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness.  Mol Diag Ther, 11(3):155-60, 2007.
• Liebzeit K, Markowitz JS, Caley CF.  New onset diabetes and atypical antipsychotics.  European Neuropsychopharmacology, 11:25–32, 2001.
• Luque CA, Ehret MJ, Rey JA.  Rimonabant (Acomplia): the first cannabinoid-1 receptor blocker for obesity.  P&T, 32(4):209-213, 2007.
• Mandalos G, Szarek BL.  New onset panic attacks in patient treated with olanzapine (letter).  J Clin Psychopharmacol, 19:191, 1999.
• Martin MC, Jaffe AJ, Wilber CH, Rounsaville BJ.  Cocaine expectancy questionnaire:  Psychometrics and underlying model.  Presented at the annual meeting of the American Psychiatric Association, New York, New York, May 2004.
• Menon LB, Boerth JM, Woolley SB, Caley CF, Goethe JW.  Antipsychotics and side effect burden: a prospective study comparing antipsychotic monotherapy versus combination therapy.  Poster presented at the annual meeting  of the College of Psychiatric and Neurologic Pharmacists. Colorado Springs, Colorado, March 2005.
• Popish SJ, Levin GM, Muthusamy K, Pandya N, Ehret MJ, Rathinavelu A.  Assessment of Ethnicity on the Butyrylcholinesterase Variant K Polymorphism.  Poster presented at the 11th Annual CPNP Meeting (Co-PI) Scottsdale, Arizona, April 2008.

• Ruaño G, Goethe JW, Windemuth A, Szarek BL.  Combinatorial cyp450 genotyping for depressed inpatients.  To be presented at the annual meeting of the American Psychiatric Association, Washington, D.C., May 2008.

• Ruaño G, Goethe JW, Windemuth A, Rahim US.  CYP genotyping in patients treated for depression.  Presented at the annual meeting of the American Psychiatric Association, San Diego, California, May 2007.

• Ruaño G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman Y, Pearlson G, Goethe JW, Schwartz HI.  Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies.  Connecticut Medicine, 71:197-200, 2007.

• Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocheria M, Windemuth de Leon AJ.  Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.  Mol Psychiatry, 12: 474-82, 2007.

• Ruaño G, Makowski G, Windemuth A, Kocherla M. Weiss S,  Goethe JW, Bower B, WU AHB, Thompson PD.  High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital:  Implications for personalized drug safety.  Personalized Medicine, 3:131-7, 2006.
• Ruaño GR, Zollner S, Goethe JW.  Drug induced metabolic syndrome (DIMS) in psychiatry:  A diagnostic need uniquely suited to pharmacogenomics.  In Wong SHY, Linder MW, Valdes R Jr. (Eds.) Pharmacogenomics and Proteomics:  Enabling the Practice of Personalized Medicine.  AACC Press, Washington, D.C., pp: 277-282, 2006.
• Shelton D, Ehret MJ.  Psychotropic Medication Adherence Patterns Among Adult Inmates.  Platform Presentation at the NCCHC Meeting, Correctional Mental Health: From Innovation to Practice, Las Vegas, Nevada, July 2008.
• Shelton D, Ehret MJ, Wakai S.  Psychotropic Medication Adherence: Implications for Post-Release Success.  Poster presented at the 11th Annual CPNP Meeting (Co-PI), Scottsdale, Arizona, April 2008.
• Shelton D, Ehret MJ, Wakai S.  Psychotropic Medication Adherence Among Adult Inmates.  Poster presented at the 20th Annual Scientific Conference Eastern Nursing Research Society, Philadelphia, PA, March 2008.

• Szarek BL, Goethe JW, Woolley SB.  Evidence-based medicine and outcome: three month follow-up of inpatients with MDD.  To be presented at the annual meeting of the American Psychiatric Association, Washington, D.C., May 2008.

• Szarek BL, Goethe JW, Woolley SB.  Indicators of treatment refractory illness and risk of suicide.  Presented at the annual meeting of the American Psychiatric Association, San Diego, California, May 2007.
• Szarek BL, Goethe JW, Fogg-Waberski JH.  Predictors of referral for ECT.  Presented at the annual meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
• Szarek BL, Goethe JW, Mucha TF.  Concurrent use of multiple antipsychotics in psychiatric inpatients.  Presented at the annual meeting of the American Psychiatric Association, New York, New York, May 2004.
• Szarek BL, Goethe JW.  Racial differences in use of antipsychotics among patients with bipolar disorder (letter).  J Clin Psychiatry, 64:614-5, 2003.
• Wilber CH, Jaffe AJ, Martin MC, Rodriguez RA, Rounsaville BJ.  Patient treatment matching with ambulatory cocaine abusers.  Presented at the annual meeting of the American Psychiatric Association, New York, NY, May 2004.
• Woolley SB, Fredman L, Goethe JW, Lincoln A, Heeren T.  Severe headaches and the risk of suicidal thoughts or behaviors.  J Nerv Ment Dis (accepted).

• Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T.  Patients’ involvement in treatment decisions and antidepressant discontinuation.  To be presented at the annual meeting of the American Psychiatric Association, Washington, D.C., May 2008.

• Woolley SB, Diefenbach, GJ, Goethe JW.  Anxiety symptoms among psychiatric outpatients: prevalence and association with suicide risk.  Poster presentation at the annual meeting of the American Public Health Association, Washington D.C., November 2007.

• Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T.  Severe headaches and the risk of subsequent suicidal thoughts or behaviors.  Presented at the annual meeting of the American Psychiatric Association, San Diego, California, May 2007.

• Woolley SB, Goethe JW, May AM, Piez DA.  Distinguishing patients who attempt suicide from patients with ideation only.  Presented at the annual meeting of the American Psychiatric Association, Toronto, Canada, May 2006.

• Woolley SB, Pavel S, Goethe JW.  Locus-of-control and outcome of treatment for MDD.  Poster presented at the annual meeting of the American Psychiatric Association, Toronto, Canada, May 2006.

• Woolley SB, Goethe JW, Woznicki B, Foley K, Hu H.  The complex relationship between SSRI side effects and discontinuation.  Poster presentation at the annual meeting of the American Psychiatric Association, New York, New York, May 2004.

• Woolley SB.  Mental illness, its treatment, and symptoms of mental and physical illness.  Presented at Boston University School of Medicine, Boston, MA, April 2004.
• Woolley SB, Goethe JW.  Establishing an evidence-based predictive system:  the importance of using local evidence.  Presented at the 47th National Conference on Mental Health Statistics, Center for Mental Health Statistics, Washington, D.C., May 2002.

• Woolley SB, Goethe JW.  A computerized clinical decision support system for behavioral health.  Presented at the 47th National Conference on Mental Health Statistics, Center for Mental Health Statistics, Washington, D.C., May 1998.

• Woolley SB, Goethe JW.  Mental health outcome assessment is not a static enterprise.  Presented at the 47th National Conference on Mental Health Statistics, Center for Mental Health Statistics, Washington, D.C., May 1998.

Top